UA103602C2 - АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА - Google Patents

АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА

Info

Publication number
UA103602C2
UA103602C2 UAA201006547A UAA201006547A UA103602C2 UA 103602 C2 UA103602 C2 UA 103602C2 UA A201006547 A UAA201006547 A UA A201006547A UA A201006547 A UAA201006547 A UA A201006547A UA 103602 C2 UA103602 C2 UA 103602C2
Authority
UA
Ukraine
Prior art keywords
drug
antibody specific
diagnostic agent
amyloid peptides
peptide
Prior art date
Application number
UAA201006547A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ежен Ванмешелен
П'єр Гроньє
Ніколя Сержан
Марі Гомпель
Андре Делакурт
Люк Бює
Лоран Прадьє
Веронік Бланшар-Брежон
Original Assignee
Енсерм (Енстітю Насьональ Де Ля Санте Е Де Ля Решер Медікалє)
Санофі-Авентіс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA103602(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Енсерм (Енстітю Насьональ Де Ля Санте Е Де Ля Решер Медікалє), Санофі-Авентіс filed Critical Енсерм (Енстітю Насьональ Де Ля Санте Е Де Ля Решер Медікалє)
Publication of UA103602C2 publication Critical patent/UA103602C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к моноклональному антителу TeiA 1.6, которое специфично связывается с N-концевой областью пептида A(8-x, где x составляет от 11 до 42, и не распознает ни A(1-40,ни A(1-42, и которое имеет высокую специфичность к пептиду A(8-x, которая определяется по образованию иммунологического комплекса между моноклональным антителом и пептидом A(8-x.
UAA201006547A 2007-10-29 2008-10-24 АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА UA103602C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29
PCT/EP2008/064432 WO2009056490A1 (en) 2007-10-29 2008-10-24 NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS

Publications (1)

Publication Number Publication Date
UA103602C2 true UA103602C2 (ru) 2013-11-11

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006547A UA103602C2 (ru) 2007-10-29 2008-10-24 АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА

Country Status (27)

Country Link
US (1) US8343493B2 (ru)
EP (1) EP2205633A1 (ru)
JP (1) JP5421277B2 (ru)
KR (1) KR20100097651A (ru)
CN (1) CN101883792B (ru)
AP (1) AP2957A (ru)
AR (1) AR069085A1 (ru)
AU (1) AU2008317705B2 (ru)
CA (1) CA2703825A1 (ru)
CL (1) CL2008003197A1 (ru)
CO (1) CO6270369A2 (ru)
CR (1) CR11396A (ru)
EA (1) EA201070539A1 (ru)
EC (1) ECSP10010142A (ru)
HN (1) HN2010000880A (ru)
IL (1) IL205398A0 (ru)
MA (1) MA31793B1 (ru)
MX (1) MX2010004660A (ru)
MY (1) MY155144A (ru)
NI (1) NI201000075A (ru)
NZ (1) NZ585000A (ru)
TN (1) TN2010000197A1 (ru)
TW (1) TW200936605A (ru)
UA (1) UA103602C2 (ru)
UY (1) UY31433A1 (ru)
WO (1) WO2009056490A1 (ru)
ZA (1) ZA201002989B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
KR20120017469A (ko) * 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
UY33253A (es) 2010-03-03 2011-09-30 Boehringer Ingelheim Int Polipéptidos de unión a a-beta
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA3004494A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
KR102862077B1 (ko) 2018-10-04 2025-09-18 게오르그-아우구스트-우니베시태트 괴팅겐 스티프퉁 외펜틀리헨 레흐츠, 우니베시태츠메디진 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2023111168A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
ECSP10010142A (es) 2010-07-30
EP2205633A1 (en) 2010-07-14
CL2008003197A1 (es) 2010-01-15
MA31793B1 (fr) 2010-10-01
MX2010004660A (es) 2010-07-30
US20110059092A1 (en) 2011-03-10
HN2010000880A (es) 2014-03-10
JP2011502139A (ja) 2011-01-20
CN101883792B (zh) 2014-08-27
NI201000075A (es) 2010-09-23
US8343493B2 (en) 2013-01-01
AP2957A (en) 2014-08-31
NZ585000A (en) 2012-08-31
IL205398A0 (en) 2010-12-30
WO2009056490A1 (en) 2009-05-07
AR069085A1 (es) 2009-12-30
EA201070539A1 (ru) 2010-10-29
AU2008317705B2 (en) 2014-06-05
CA2703825A1 (en) 2009-05-07
CO6270369A2 (es) 2011-04-20
CR11396A (es) 2012-10-18
AP2010005249A0 (en) 2010-06-30
TN2010000197A1 (en) 2011-11-11
CN101883792A (zh) 2010-11-10
ZA201002989B (en) 2011-07-27
UY31433A1 (es) 2009-05-29
MY155144A (en) 2015-09-15
JP5421277B2 (ja) 2014-02-19
AU2008317705A1 (en) 2009-05-07
TW200936605A (en) 2009-09-01
KR20100097651A (ko) 2010-09-03

Similar Documents

Publication Publication Date Title
UA103602C2 (ru) АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
UA89017C2 (ru) ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ ТНФСФ13б
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
WO2006094192A3 (en) Humanized l243 antibodies
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EP2380592A3 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UA111818C2 (uk) Антитіло проти csf-1r
TW200510459A (en) RG1 antibodies and uses thereof
EP2535351A3 (en) Dual specificity antibody fusions
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
GEP20156214B (en) Monoclonal antibodies
UA98983C2 (ru) Антитело против гепсидина и его применение
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ595863A (en) Antibodies to egfl7 and methods for their use
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
WO2006086799A3 (en) Prion-specific peptide reagents
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
MX2007010220A (es) Peptidos para la deteccion de anticuerpo para el virus del sindrome respiratorio reproductivo porcino.
IN2013MN00513A (ru)
WO2006091421A3 (en) Peptides for detection of antibody to ehrlichia ewingii
IN2014DN07875A (ru)
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.